Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acorda Therapeutics has confirmed that based on feedback it received in a meeting with the FDA it will conduct an additional phase III trial of Fampridine-SR in people with multiple sclerosis.
Subscribe to our email newsletter
Typically, the FDA requires two adequate and well-controlled studies to establish substantial evidence of effectiveness.
In September 2006, Acorda said the drug improved the walking speed in significantly more patients than placebo in a previous trial. With the additional trial the company intends to determine the effectiveness of Fampridine-SR and expects that the trial will be the same or shorter duration than the first phase III study.
Acorda said it would continue to consult with the FDA on protocol development for both of these studies and any additional requirements that might be needed.